RxSight, Inc. - Common Stock (RXST)

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”). RxSight investors have until September 22, 2025 to file a lead plaintiff motion.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”). RxSight investors have until September 22, 2025 to file a lead plaintiff motion.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025. RxSight describes itself as a “commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses.”

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, inclusive.

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of (“RxSight” or the “Company”) (NASDAQ: RXST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, captioned Makaveev v. RxSight, Inc., et al., Case No. 8:25-cv-01596, on behalf of persons and entities that purchased or otherwise acquired RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of the securities laws.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of the securities laws.

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of federal securities laws.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options

SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) --

The Law Offices of Frank R. Cruz continues its investigation of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) on behalf of investors concerning the Company’s possible violations of federal securities laws.

ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time.

ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025.

ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas.